Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company's commercially available iTANK platform, is pleased to announce that its Chief Development Officer and co-founder, Di Yu, has been awarded the prestigious Senior Investigator Award from the Swedish Cancer Society (Cancerfonden).
The award provides a research grant of SEK 3,885,000, distributed over 3 years. This funding supports established cancer researchers in dedicating themselves full-time to advancing high-impact cancer research, aligning perfectly with Di Yu's ongoing work in CAR T-cell therapy development.
Di Yu, who also serves as Head of Technical Operations at Elicera, commented:
"I am honored to have been awarded the Cancerfonden Senior Investigator position - a recognition that strengthens my long-term dedication to advancing CAR-T cell therapy. This support gives me the opportunity to continue building our research program, deepen collaborations, and accelerate our preclinical works toward clinical practices that can make a real difference for patients."
The Senior Investigator Award, granted by Cancerfonden, enables recipients without permanent senior academic positions (such as professor or senior lecturer) to focus exclusively on cancer research for an extended period, with the potential for renewal up to a total of six years (3+3 structure).
This recognition underscores Di Yu's contributions to the field. Elicera Therapeutics congratulates Di Yu on this achievement.